Telo Genomics Corp Stock Profit Margin
| 3D0A Stock | EUR 0.06 0.03 93.44% |
Telo Genomics Corp fundamentals help investors to digest information that contributes to Telo Genomics' financial success or failures. It also enables traders to predict the movement of Telo Stock. The fundamental analysis module provides a way to measure Telo Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telo Genomics stock.
Telo |
Telo Genomics Corp Company Profit Margin Analysis
Telo Genomics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Telo Genomics Corp has a Profit Margin of 0.0%. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Diagnostics & Research industry. The profit margin for all Germany stocks is 100.0% lower than that of the firm.
Telo Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telo Genomics' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Telo Genomics could also be used in its relative valuation, which is a method of valuing Telo Genomics by comparing valuation metrics of similar companies.Telo Genomics is currently under evaluation in profit margin category among its peers.
Telo Fundamentals
| Return On Equity | -0.78 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 13.04 M | |||
| Shares Outstanding | 59.42 M | |||
| Shares Owned By Insiders | 6.52 % | |||
| Shares Owned By Institutions | 1.83 % | |||
| Price To Book | 8.88 X | |||
| EBITDA | (2.05 M) | |||
| Net Income | (2.11 M) | |||
| Cash And Equivalents | 1.96 M | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 40 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 12.88 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (1.79 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 10 | |||
| Beta | 1.87 | |||
| Market Capitalization | 11.92 M | |||
| Total Asset | 2.83 M | |||
| Net Asset | 2.83 M |
About Telo Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telo Genomics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telo Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telo Genomics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Telo Stock
Telo Genomics financial ratios help investors to determine whether Telo Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Telo with respect to the benefits of owning Telo Genomics security.